

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1 STR
```

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:59:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2133 TO ITERATE
```

93.8% PROCESSED 2000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**	
	BATCH	**COMPLETE**	
PROJECTED ITERATIONS:	39890 TO	45430	
PROJECTED ANSWERS:	2 TO	129	

L2 2 SEA SSS SAM L1

```
=> s l1 ful
FULL SEARCH INITIATED 15:59:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 44032 TO ITERATE
```

100.0% PROCESSED 44032 ITERATIONS 130 ANSWERS  
SEARCH TIME: 00.00.01

L3 130 SEA SSS FUL L1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 15:59:32 ON 14 AUG 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2009 VOL 151 ISS 8  
 FILE LAST UPDATED: 13 Aug 2009 (20090813/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolICY.html>



This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 13  
 L4 4 L3

=> d abs fbib fhitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
 GI



AB Title compds. I [wherein R1, R2 = OH or (cyclo)alkoxy; R3, R31 = H or alkyl; R4 = OH, alkoxy or alkylcarbonyloxy; R5 = H or alkyl; R6 = H, halo, alkyl or alkoxy; R7 = (un)substituted NH<sub>2</sub>; etc., or their salts and the N-oxides, and the salts of the N-oxides] were prepared as PDE4 inhibitors. For instance, II (R = OH) was synthesized by hydrolysis of its ester II (R

= OAc) with Cs<sub>2</sub>CO<sub>3</sub> in methanol. Representative I, including II (R = OH), were found to inhibit PDE4B2 with pIC<sub>50</sub> values of 6.42 - 9.02. Therefore, I and pharmaceutical compns. thereof are useful for treating PDE-mediated disorders, such as respiratory diseases.

AN 2005:1026938 CAPLUS  
 DN 143:326233  
 TI Preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases  
 IN Schmidt, Beate; Kautz, Ulrich  
 PA Altana Pharma AG, Germany; Kautz, Ulrich  
 SO PCT Int. Appl., 107 pp.  
 CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087745	A1	20050922	WO 2005-EP51054	20050309
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2004-100990	A 20040310
				EP 2004-106677	A 20041217
AU	2005221832	A1	20050922	AU 2005-221832	20050309
				EP 2004-100990	A 20040310
				EP 2004-106677	A 20041217
				WO 2005-EP51054	W 20050309
CA	2558391	A1	20050922	CA 2005-2558391	20050309
				EP 2004-100990	A 20040310
				EP 2004-106677	A 20041217
				WO 2005-EP51054	W 20050309
EP	1725534	A1	20061129	EP 2005-740073	20050309
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			EP 2004-100990	A 20040310
				EP 2004-106677	A 20041217
				WO 2005-EP51054	W 20050309
CN	1926113	A	20070307	CN 2005-80006855	20050309
				EP 2004-100990	A 20040310
				EP 2004-106677	A 20041217
				WO 2005-EP51054	W 20050309
BR	2005008481	A	20070731	BR 2005-8481	20050309
				EP 2004-100990	A 20040310
				EP 2004-106677	A 20041217
				WO 2005-EP51054	W 20050309
JP	2007527901	T	20071004	JP 2007-502343	20050309
				EP 2004-100990	A 20040310

			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
ZA 2006006669	A	20080227	ZA 2006-6669		20060811
			EP 2004-100990	A	20040310
MX 2006009892	A	20070301	MX 2006-9892		20060831
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
US 20070185149	A1	20070809	US 2006-591480		20060927
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
NO 2006004415	A	20061010	NO 2006-4415		20060929
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
KR 2006130697	A	20061219	KR 2006-720318		20060929
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
IN 2006MN01169	A	20070413	IN 2006-MN1169		20061003
			EP 2004-100990	A	20040310
			WO 2005-EP51054	W	20050309
OS	CASREACT 143:326233; MARPAT 143:326233				
IT	865306-83-8P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (inhibitor; preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases)				
RN	865306-83-8 CAPLUS				
CN	Benzamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N-[2-(4-morpholinyl)ethyl]-, rel- (CA INDEX NAME)				

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1, R2 = independently OH and F-substituted/cyclo/alkoxy, 2,2-difluoroethoxy, etc.; R1-R2 = alkylenedioxy; R3, R31 = independently H, alkyl; R4 = H, alkyl, OR41; R5 = OR51; R41, R51 = independently H, alkoxy/hydroxy/F-substituted/alkyl, alkylcarbonyl; R6 = H, halo, alkyl, alkoxy; R61 = H, alkoxy/alkyl; R7 = cycloalkyl, (un)substituted alkyl, 3-7 membered fully saturated heteriocycl, etc.; their N-oxides, and their salts] were prepared as effective PDE4 inhibitors for treating respiratory diseases. Thus, acylation of amine rac-II with methoxyacetic acid and saponification gave phenanthridine rac-III. Selected I inhibited PDE4 with

-log IC50 values in the range of 8,42 to 9.73 mol/l.

AN 2005:1001807 CAPLUS

DN 143:306198

TI Preparation of 2- or 3-hydroxy-6-(substituted-carbonylamino)phenylphenanthridines as PDE4 inhibitors

IN Schmidt, Beate; Flockerzi, Dieter; Hatzelmann, Armin; Zitt, Christof; Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; Kautz, Ulrich

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent


LA English

## FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084104	A2	20050915	WO 2005-EP51025	20050308
	WO 2005084104	A3	20051013		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
AU	2005220034	A1	20050915	AU 2005-220034	20050308
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
CA	2558375	A1	20050915	CA 2005-2558375	20050308
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
EP	1745025	A2	20070124	EP 2005-729761	20050308
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
CN	1926111	A	20070307	CN 2005-80006520	20050308
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
JP	2007527899	T	20071004	JP 2007-502338	20050308
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
BR	2005008361	A	20071120	BR 2005-8361	20050308
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
ZA	2006006635	A	20080528	ZA 2006-6635	20060810
				EP 2004-100959	A 20040309
MX	2006009893	A	20061003	MX 2006-9893	20060831
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
US	20070191414	A1	20070816	US 2006-591478	20060927
				EP 2004-100959	A 20040309
				EP 2005-100545	A 20050127
				WO 2005-EP51025	W 20050308
NO	2006004417	A	20061010	NO 2006-4417	20060929

KR 2006124784	A	20061205	EP 2004-100959	A	20040309
			EP 2005-100545	A	20050127
			WO 2005-EP51025	W	20050308
IN 2006MN01171	A	20070406	KR 2006-720594		20061002
			EP 2004-100959	A	20040309
			EP 2005-100545	A	20050127
			WO 2005-EP51025	W	20050308
OS	CASREACT 143:306198; MARPAT 143:306198		IN 2006-MN1171		20061003
IT	1044694-13-4		EP 2004-100959	A	20040309
	RL: PRPH (Prophetic)		WO 2005-EP51025	W	20050308

RN 1044694-13-4 CAPLUS  
 CN Butanediamide, N1-[3-(9-ethoxy-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl)phenyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = OH, alkoxy, cycloalkoxy, etc.; R2 = OH, cycloalkylmethoxy, cycloalkoxy, etc. or R1 and R2 together form alkylenedioxy group; R3 = H or alkyl; R4 = OR9 and R5 = H or alkyl or R4 = H or alkyl and R5 = OR9; R6 = H or alkyl; R7 = (un)substituted guanidinyl; R8 = H, halo, nitro, etc.; R9 = H, alkyl, alkoxyalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as phosphodiesterase 4 (PDE4) inhibitors. Thus, e.g., II was prepared by coupling of 4-((2RS,4aRS,10bRS)-2-acetoxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzoic acid with the resp. guanidinyl derivative followed by hydrolysis. The activity of I was evaluated using scintillation proximity assays and it was revealed that selected compds. of the invention displayed -log IC50 values higher than 7.5. I as inhibitor of PDE4 should provide useful in the treatment of respiratory disorders. Pharmaceutical compns. comprising I are disclosed.

AN 2005:902858 CAPLUS  
 DN 143:248297  
 TI Preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors  
 IN Schmidt, Beate; Flockerzi, Dieter; Hatzelmann, Armin; Zitt, Christof;  
     Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; Kautz, Ulrich  
 PA Altana Pharma A.-G., Germany  
 SO PCT Int. Appl., 72 pp.  
     CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005077906	A1	20050825	WO 2005-EP50708	20050217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			EP 2004-3592	A 20040218
	AU 2005212857	A1	20050825	AU 2005-212857	20050217
				EP 2004-3592	A 20040218
				WO 2005-EP50708	W 20050217
	CA 2556086	A1	20050825	CA 2005-2556086	20050217
				EP 2004-3592	A 20040218
				WO 2005-EP50708	W 20050217
EP	1720835	A1	20061115	EP 2005-708038	20050217
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			EP 2004-3592	A 20040218
				WO 2005-EP50708	W 20050217
JP	2007523130	T	20070816	JP 2006-553593	20050217
				EP 2004-3592	A 20040218
				WO 2005-EP50708	W 20050217
US	20070167482	A1	20070719	US 2006-589082	20060905
				EP 2004-3592	A 20040218
				WO 2005-EP50708	W 20050217
OS	CASREACT 143:248297; MARPAT 143:248297				
IT	862993-72-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors)				
RN	862993-72-4 CAPLUS				
CN	Benzamide, N-[(diethylamino)iminomethyl]-4-[(2R,4aR,10bR)-9- (difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6- phenanthridinyl]-, rel- (CA INDEX NAME)				

Relative stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
 GI



AB The title compds. I [wherein R1 and R2 = independently OH, alkoxy, cycloalkyloxy, cycloalkylmethoxy, or fluorinated alkoxy; or R1 and R2 together form alkylenedioxy; R3 = H or alkyl; R31 = H or alkyl; R4 = H, alkyl, fluorinated alkyl, alkoxyalkyl, hydroxyalkyl, or alkylcarbonyl; R5 = H or alkyl; R6 = H, alkyl, CF<sub>3</sub>, alkoxy, fluorinated alkoxy, cycloalkyloxy, cycloalkylmethoxy, H, NO<sub>2</sub>, CN, OH, alkylcarbonyloxy, NH<sub>2</sub>, alkylamino, dialkylamino, Ph, Ph-alkyl, alkylcarbonylamino, PhO, or (un)substituted CO<sub>2</sub>H; R7 = H, alkyl, OH, halo, alkoxy, fluorinated alkoxy, cycloalkyloxy, cycloalkylmethoxy, or (un)substituted CO<sub>2</sub>H] or salts, N-oxides, or salts of the N-oxides thereof are prepared as phosphodiesterase

(PDE) 4 inhibitors. For example, the compound II was prepared in a multi-step synthesis. I showed inhibitory activity with "-logIC50" of 7.09 to 9.74 against human PDE4. I are useful for the treatment of respiratory disorders or dermatosis (no data).

AN 2004:203669 CAPLUS  
 DN 140:235615  
 TI Preparation of 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors  
 IN Kautz, Ulrich; Schmidt, Beate  
 PA Altana Pharma A.-G., Germany  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019944	A1	20040311	WO 2003-EP9547	20030828
	W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
				EP 2002-19335	A 20020829
	CA 2495827	A1	20040311	CA 2003-2495827	20030828
				EP 2002-19335	A 20020829
				WO 2003-EP9547	W 20030828
	AU 2003255493	A1	20040319	AU 2003-255493	20030828
	AU 2003255493	B2	20090219	EP 2002-19335	A 20020829
				WO 2003-EP9547	W 20030828
	EP 1539164	A1	20050615	EP 2003-790931	20030828
	EP 1539164	B1	20061220	EP 2002-19335	A 20020829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			WO 2003-EP9547	W 20030828
				EP 2002-19335	A 20020829
	JP 2005539043	T	20051222	JP 2004-532133	20030828
				EP 2002-19335	A 20020829
				WO 2003-EP9547	W 20030828
	AT 348616	T	20070115	AT 2003-790931	20030828
				EP 2002-19335	A 20020829
	ES 2279215	T3	20070816	ES 2003-790931	20030828
				EP 2002-19335	A 20020829
	US 20050239817	A1	20051027	US 2005-524819	20050218
	US 7329676	B2	20080212	EP 2002-19335	A 20020829
				WO 2003-EP9547	W 20030828
	US 20080319067	A1	20081225	US 2007-710	20071217
				EP 2002-19335	A 20020829
				WO 2003-EP9547	W 20030828
				US 2005-524819	A1 20050218
OS	MARPAT 140:235615				
IT	669000-72-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				


## (Uses)

(drug candidate; preparation of phenanthridine derivs. as PDE-4 inhibitors)

RN 669000-72-0 CAPLUS

CN Acetamide, N-[4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT